Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019
04 mars 2019 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
Trevena to Present at the 21st Annual BIO CEO & Investor Conference
05 févr. 2019 18h58 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options...
Trevena Announces $10 Million Registered Direct Offering of Common Stock
30 janv. 2019 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused...
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
28 janv. 2019 07h00 HE
|
Trevena Inc.
– Company announces initial path forward on oliceridine NDA – – Company to host conference call on Monday, January 28 at 8:30 a.m. ET – CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) --...
National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology
13 déc. 2018 16h01 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer
10 déc. 2018 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring
08 nov. 2018 07h00 HE
|
Trevena Inc.
– $70.0 Million of Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 – – Company to host conference call and webcast at 8:00am EST – CHESTERBROOK, Pa., Nov. 08, 2018 (GLOBE...
Trevena Receives Complete Response Letter for Oliceridine from FDA
02 nov. 2018 13h42 HE
|
Trevena Inc.
Company to host conference call and webcast on November 5th CHESTERBROOK, Pa., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) today announced the Company has received a Complete...
Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting
12 oct. 2018 16h01 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) today announced a poster presentation at ANESTHESIOLOGY® 2018, the national conference for the American Society of...
Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
11 oct. 2018 17h04 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced the outcome of the meeting of the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic...